Charles River Laboratories
Provider of research models, nonclinical drug-development services, and manufacturing quality-control testing.
Something off on this page? Send us feedback.
Profile
Sells research models and related services, performs outsourced discovery and regulated nonclinical safety studies, and supplies microbial and biologics quality-control testing. Most revenue comes from services, with the portfolio now refocused on regulated testing after divesting CDMO, Cell Solutions, and selected European discovery operations.
Supplies research models and related services, runs outsourced discovery and safety studies, and provides manufacturing quality-control testing across its reporting segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The latter houses Microbial Solutions and Biologics Testing Solutions following recent divestitures of CDMO, Cell Solutions, and selected European discovery sites.
Serves pharmaceutical and biotechnology companies, government agencies, hospitals, and academic institutions through operations spanning North America, Europe, and Asia. Controlled model production, animal-health monitoring, regulated study execution, bioanalysis, and microbial and biologics testing let clients outsource work from early discovery through nonclinical development and product release.
Animal-welfare and laboratory regulations govern much of the work, while safety-assessment capacity depends partly on a compliant, timely supply of non-human primates.
Company facts
Key statistics
Year to date +44.0% · Average volume (30d) 935.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Piper Sandler | Target | $300 | |||
| Aug 10, 2026 | Mizuho Securities | Target | $230 | $264 | ||
| Aug 7, 2026 | Morgan Stanley | Reiterate | Overweight | $260 | $300 | |
| Aug 6, 2026 | Robert W. Baird | Target | $213 | $291 | ||
| Aug 6, 2026 | RBC Capital | Reiterate | Outperform | $215 | $282 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $2.74 | $3.02 | +10.2% | $977.2M | $1.00B | +2.8% | +11.36% |
| May 7, 2026Q1 FY26 | $1.96 | $2.06 | +5.1% | $977.5M | $995.8M | +1.9% | −2.23% |
| Feb 18, 2026Q4 FY25 | $2.33 | $2.39 | +2.6% | $987.0M | $994.2M | +0.7% | +3.95% |
| Nov 5, 2025Q3 FY25 | $2.32 | $2.43 | +4.7% | $987.2M | $1.00B | +1.8% | +1.90% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $984.2M | $1.03B | $1.00B | $994.2M | $995.8M | $1.00B | |
| Gross profit | $317.7M | $357.1M | $338.8M | $307.9M | $279.3M | $363.4M | |
| Operating income | $74.7M | $100.1M | $133.8M | $120.2M | $119.9M | $119.9M | |
| Net income | $25.5M | $52.3M | $54.4M | −$276.6M | −$14.8M | −$1.5M | |
| Diluted EPS | $0.50 | $1.06 | $1.10 | −$5.62 | −$0.30 | −$0.03 | |
| Gross margin | 32.3% | 34.6% | 33.7% | 31.0% | 28.0% | 36.2% | |
| Operating margin | 7.6% | 9.7% | 13.3% | 12.1% | 12.0% | 11.9% |
Fiscal years (4-quarter sums)FY21 $3.54B · FY22 $3.98B · FY23 $4.13B · FY24 $4.05B · FY25 $4.02B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 27, 2026Cash & short-term investments $192.0M · Total debt $3.03B · Total assets $7.53B · Shareholders' equity $2.84B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 48.17M · Float 47.62M · 98.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 4.24M | 8.80% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 3.80M | 7.89% | 13F | Aug 7, 2026 |
| Wellington Investment Advisors Holdings LLP | 3.74M | 7.25% | 13G | Nov 8, 2024 |
| Vanguard Capital Management LLC | 3.15M | 6.54% | 13F | Aug 13, 2026 |
| Invesco Ltd. | 2.98M | 6.20% | 13G | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | James C. Foster | director | −33,561 | $300.00 |
| Aug 19, 2026 | Shannon M. Parisotto | officer: CEVP, Disc & Safety Assessment | −2,039 | $294.12 |
| Aug 18, 2026 | Nancy C. Andrews | director | −573 | $285.24 |
| Aug 11, 2026 | Shannon M. Parisotto | officer: CEVP, Disc & Safety Assessment | −3,714 | $279.66 |
| Aug 11, 2026 | Birgit Girshick | director, officer: Chief Executive Officer | −6,500 | $279.90 |
Peers
- Labcorp
Central labs and nonclinical services overlap CRL's DSA workflow.
- Thermo Fisher Scientific
Broad overlap in CRO, lab services, instruments, and microbiology QC.
- IQVIA
Clinical, lab, and discovery-services overlap around biopharma R&D.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Charles River Laboratories | $291.50 | +0.04% | $14.04B | — | 23.7 | 3.5 | −2.7% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| Median | 32.5 | 19.2 | 2.5 | +8.7% |